Eli Lilly’s Efsitora Meets Key Endpoints in Phase III Trials for Type 2 Diabetes
US major Eli Lilly and Company (NYSE: LLY) presented detailed results from the Phase III...
Diabetes
Eccogene Announces First Patient Dosing in Phase Ib Study of AZD5004/ECC5004 in China
Sino-US firm Eccogene Inc., a partner of UK major AstraZeneca (AZ, NASDAQ: AZN), announced the...
Sanofi’s Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes
Tzield (teplizumab), the world’s first and only targeted therapy designed to delay the onset of...
Novo Nordisk Partners with Alibaba Health to Launch Weight Management Hub”
Denmark-based Novo Nordisk (NYSE: NVO) has entered into a partnership with China’s Alibaba Health Information...
Hasten Biopharmaceutical Accelerates Asia-Pacific Expansion With 11 MAT Transfers
China-based Hasten Biopharmaceutical Co., Ltd, backed by CBC Group, announced the completion of Market Authorization...
Lilly Launches Mounjaro Multi-Dose Pen in China for Diabetes and Weight Management
US-based Eli Lilly & Co. (NYSE: LLY) announced the launch of Mounjaro (tirzepatide multi-dose prefilled...
Shandong Boan Partners with Shanghai Pharma for BA5101 Diabetes Drug
China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced a strategic collaboration with Shanghai Pharmaceuticals...
Novo Nordisk China Restructures to Form New Obesity and Diabetes Department
Danish pharmaceutical giant Novo Nordisk’s (NYSE: NVO) China unit announced an organizational restructuring, merging its...
Huadong Medicine’s HDM1010 Gets FDA Nod for Phase I Trial in T2D
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...
Salubris Pharmaceuticals’ Allisartan-Indapamide Hybrid Wins NMPA Approval
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, announced that it has...
Eli Lilly Partners with Camurus on Long-Acting Cardiovascular and Metabolic Health Products
US-based Eli Lilly & Co. (NYSE: LLY) entered into a collaboration and licensing agreement with...
Hengrui Pharmaceuticals Gains NMPA Approval for HRS9531 Clinical Study in Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
Regend Therapeutics Gains NMPA Approval for Phase I/II Study of REGEND003 in Diabetes-Related CKD
Suzhou-based stem cell therapy specialist Regend Therapeutics announced that it has received approval from China’s...
Hengrui Pharmaceuticals’ Retagliptin and Metformin Approved by NMPA for Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received marketing...
Roche’s Susvimo Gets FDA Approval for Diabetic Retinopathy
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg/mL intravitreal ocular...
Suzhou’s PegBio Launches Hong Kong IPO Amid Pipeline Progress
Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO,...
Gan & Lee Pharmaceuticals Signs PDP Agreement with Brazilian Health Ministry
Gan & Lee Pharmaceuticals (SHA: 603087) announced the signing of Parcerias para o Desenvolvimento Produtivo...
Lepu Medical’s MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a provider of cardiovascular disease solutions,...
Zhongsheng Pharma’s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose...
AstraZeneca’s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines
UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY)...